» Articles » PMID: 24344013

Characterization of Immunohistochemical Markers in Triple Negative Breast Carcinomas

Overview
Journal J BUON
Specialty Oncology
Date 2013 Dec 18
PMID 24344013
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Triple negative (TN) breast carcinomas (estrogen receptor/ER, progesterone receptor/PR and HER-2/neu negative) constitute 15-25% of all breast carcinomas and have been correlated with aggressive behavior and poor prognosis. Our aim was to describe and characterize the immunophenotype of these tumors in a group of patients from Turkey.

Methods: We used the immunohistochemical markers CK5/6, CK14, EGFR, E-cadherin, p53 and androgen receptor. Formalin-fixed, paraffin-embedded tissues from 51 breast carcinoma patients (36 TN and 15 non TN) were included into this study.

Results: The mean values of the distribution of immunohistochemical markers in TN vs non-TN groups were as follows: CK5/6 78.4 vs 5.3%, CK14 84.8 vs 8%, EGFR 87.2 vs 8%, E-cadherin 96.9 vs 53.2%, p53 87.3 vs 7.3% and androgen receptor 89.5 vs 33.3% (all p-values<0.001). CK5/6 stained significantly different in the grade 2 and 3 cases (p=0.035) in the TN group.The other markers demonstrated no significant differences between grades.

Conclusion: TN breast carcinomas in Turkish patients express basal cytokeratins, and have high levels of p53 compared to non-TN breast carcinomas.

Citing Articles

Identifying the effectiveness of 3D culture systems to recapitulate breast tumor tissue in situ.

Ludwik K, Greathouse F, Han S, Stauffer K, Brenin D, Stricker T Cell Oncol (Dordr). 2023; 47(2):481-496.

PMID: 37776423 PMC: 11090829. DOI: 10.1007/s13402-023-00877-8.


Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer.

Badowska-Kozakiewicz A, Budzik M, Liszcz A, Sobieraj M, Czerw A, Sobol M Arch Med Sci. 2019; 15(6):1433-1442.

PMID: 31749871 PMC: 6855147. DOI: 10.5114/aoms.2018.79568.


Retrospective evaluation of histopathological examinations in invasive ductal breast cancer of no special type: an analysis of 691 patients.

Badowska-Kozakiewicz A, Liszcz A, Sobol M, Patera J Arch Med Sci. 2017; 13(6):1408-1415.

PMID: 29181072 PMC: 5701672. DOI: 10.5114/aoms.2015.53964.